Arrowhead Pharmaceuticals Inc (ARWR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arrowhead Pharmaceuticals Inc (ARWR) has a cash flow conversion efficiency ratio of 0.041x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($20.49 Million) by net assets ($503.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Arrowhead Pharmaceuticals Inc to measure how much of total assets are equity-financed.
Arrowhead Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how Arrowhead Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ARWR cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Arrowhead Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arrowhead Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Agree Realty Corporation
NYSE:ADC
|
0.023x |
|
Dixon Technologies (India) Limited
NSE:DIXON
|
0.044x |
|
Autoliv Inc
NYSE:ALV
|
-0.029x |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
0.063x |
|
China Merchants Shekou Industrial Zone Holdings
SHE:001979
|
0.019x |
|
CubeSmart
NYSE:CUBE
|
0.049x |
|
Brixmor Property
NYSE:BRX
|
0.046x |
|
TORAY INDUSTRIES ADR/2
F:6HK
|
N/A |
Annual Cash Flow Conversion Efficiency for Arrowhead Pharmaceuticals Inc (1997–2025)
The table below shows the annual cash flow conversion efficiency of Arrowhead Pharmaceuticals Inc from 1997 to 2025. For the full company profile with market capitalisation and key ratios, see Arrowhead Pharmaceuticals Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $503.42 Million | $179.55 Million | 0.357x | +114.72% |
| 2024-09-30 | $191.06 Million | $-462.85 Million | -2.423x | -352.04% |
| 2023-09-30 | $287.16 Million | $-153.89 Million | -0.536x | -64.69% |
| 2022-09-30 | $418.34 Million | $-136.13 Million | -0.325x | -177.70% |
| 2021-09-30 | $408.82 Million | $171.22 Million | 0.419x | +302.75% |
| 2020-09-30 | $461.78 Million | $-95.39 Million | -0.207x | -129.13% |
| 2019-09-30 | $244.04 Million | $173.03 Million | 0.709x | +243.00% |
| 2018-09-30 | $95.24 Million | $-47.22 Million | -0.496x | -67.49% |
| 2017-09-30 | $80.87 Million | $-23.94 Million | -0.296x | +56.34% |
| 2016-09-30 | $95.02 Million | $-64.43 Million | -0.678x | -13.11% |
| 2015-09-30 | $109.62 Million | $-65.71 Million | -0.599x | -180.92% |
| 2014-09-30 | $165.99 Million | $-35.42 Million | -0.213x | +71.15% |
| 2013-09-30 | $25.73 Million | $-19.03 Million | -0.740x | +57.53% |
| 2012-09-30 | $8.81 Million | $-15.34 Million | -1.741x | -305.88% |
| 2011-09-30 | $12.56 Million | $-5.39 Million | -0.429x | +54.98% |
| 2010-09-30 | $8.08 Million | $-7.70 Million | -0.953x | +69.69% |
| 2009-09-30 | $4.86 Million | $-15.28 Million | -3.145x | -40.26% |
| 2008-09-30 | $12.30 Million | $-27.58 Million | -2.242x | -148.54% |
| 2007-09-30 | $26.46 Million | $-23.87 Million | -0.902x | -92.76% |
| 2006-09-30 | $31.61 Million | $-14.79 Million | -0.468x | -44.09% |
| 2005-09-30 | $28.02 Million | $-9.10 Million | -0.325x | -57.54% |
| 2004-09-30 | $11.23 Million | $-2.31 Million | -0.206x | -85.73% |
| 2003-09-30 | $1.42 Million | $-157.60K | -0.111x | -262.64% |
| 2002-09-30 | $-1.55 Million | $-105.83K | 0.068x | +8.82% |
| 2001-09-30 | $-1.30 Million | $-81.81K | 0.063x | -11.57% |
| 2000-09-30 | $-1.13 Million | $-80.09K | 0.071x | +100.61% |
| 1999-09-30 | $-996.10K | $-35.22K | 0.035x | +101.32% |
| 1998-09-30 | $-2.63 Million | $-46.15K | 0.018x | +1091.72% |
| 1997-09-30 | $-2.58 Million | $4.56K | -0.002x | -- |
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, a… Read more